Identifying the Neural Basis of Capability for Suicide
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hailey Wright, B.Arts. Sc
- Phone Number: 4168646060
- Email: Hailey.Wright@unityhealth.to
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 0C1
- St. Michael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria for patients:
- Age between 18-70
- Capability of giving informed consent
- Not currently pregnant or lactating (due to potential confounding of brain activity as a result of differing hormone levels)
Exclusion criteria for patients:
- Lifetime history of any substance abuse, psychosis
- Current use of any opioid acting drugs
- Current use of any prescription pain medication
- Use of over the counter pain medications within 15 hours of brain scan
- For daily users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 12 hours of brain scan
- For as needed users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 2 weeks of brain scan. This is because non-daily use will have more unpredictable effects on brain imaging results than those who are using these medications on a regular basis. The 2 weeks will ensure the drug is not in the system.
- Medical condition requiring immediate investigation or treatment
- Participation in experimental treatment trials for the study duration.
Healthy control inclusion criteria: Ages between 18 and 70 years, capable of giving informed consent, not pregnant or lactating, no lifetime history of Axis I/II disorders, no history of antidepressant or mood stabilizer use, no treatment for acute or ongoing medical condition, no use of any over the counter pain medication for at least 15 hours prior to the brain scan.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy Controls
Subjects will have no personal or family psychiatric history and no suicide attempts.
|
An fMRI scan will be conducted to collect neuroimaging data.
The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
|
|
Patients with SI
Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >=2).
|
An fMRI scan will be conducted to collect neuroimaging data.
The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neural network underlying acquired capability for suicide
Time Frame: 2 weeks
|
Measure the correlation between acquired capability for suicide and brain activity during a pressure pain task using fMRI in patients
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between pain task performance and acquired capability for suicide
Time Frame: 2 weeks
|
Assess the association between pain task ratings and acquired capability for suicide in patients
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sakina Rizvi, PhD, Unity Health Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SRO-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Suicidal Ideation
-
NCT07365579Not yet recruitingSuicidal Ideation and Behavior
-
NCT07343258RecruitingSuicide | Suicidal Ideation and Behavior | Crisis Intervention
-
NCT07321171RecruitingSuicidal Ideation and Behavior
-
NCT01829620CompletedSuicidal and Self-injurious Behavior | Suicidal Ideation Active
-
NCT01300169CompletedSuicidal and Self-injurious Behavior | Suicidal Ideation Active
-
NCT02691221CompletedSuicide, Suicidal Ideation
-
NCT07559955RecruitingSuicidal Ideation and Behavior
-
NCT06885047Not yet recruitingSuicidal Ideation/Behavior
-
NCT06686498Active, not recruitingSuicidal Ideation | Suicidal Ideation and Behaviors
-
NCT07356492RecruitingHealth | Reintegration Difficulties | Suicidal Ideation and Behaviors | Connectedness
Clinical Trials on fMRI
-
NCT01212237Withdrawn
-
NCT05455827Completed
-
NCT01908647UnknownTraumatic Brain Injury | Post Traumatic Stress Disorder
-
NCT03190486CompletedMagnetic Resonance Imaging | Neuronal Activity
-
NCT03224975TerminatedMagnetic Resonance Imaging | Neuronal Activity
-
NCT07468032RecruitingStroke | EEG | fNIRS | Temporal Perturbation | Virtual Lesion | TMS | Stroke Lesions | Action Slowing
-
NCT05299749RecruitingSchizophrenia | Treatment-resistant Schizophrenia | Auditory Hallucination